Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Guides / Retatrutide

Retatrutide, explained plainly

What it is, why it acts on three receptors, how long it lasts in the body, and how far it has got with regulators.

5 min read · 2026-11-17

The short version

Retatrutide is a single peptide built to switch on three receptors at once: the GIP receptor, the GLP-1 receptor and the glucagon receptor 16. It was first published under the developer code LY3437943 6.

In its trials it is given as an injection under the skin once a week 1. It is investigational: the phase 3 report published in 2026 describes it as under clinical development, and no source on its page records a marketing authorization 4.

One molecule, what it acts on

What it binds, and what each receptor is known to do. Pick one.

RetatrutideGIPGLP-1GCG

GIP receptor. In vitro the molecule is more active here than at the other two receptors. In obese mice the discovery paper credits GIP and GLP-1 receptor activity with the reduction in calorie intake 6.

Why three receptors

The idea came in steps. A review of the mechanisms describes the sequence: the known actions of GLP-1 and of GIP alone, then single molecules that activate both of those receptors, and now molecules that also bind the glucagon receptor 8.

In obese mice, the discovery paper credits the fall in calorie intake to GIP and GLP-1 receptor activity, and reports that weight loss was increased by a rise in energy expenditure through the glucagon receptor 6. That is a finding in mice. An animal result is not a result in people.

What each receptor adds in people is less settled. A scoping review of dual and triple agonists reports that the extra benefit from the glucagon receptor was largely unexpected, and that whether the three signaling pathways help or hinder each other when stimulated together is not known 8.

How long it lasts

In the phase 1b trial in adults with type 2 diabetes, the half-life was approximately 6 days 5. A half-life is the time it takes for the amount in the blood to fall by half. A half-life of about six days is what makes a once-weekly schedule possible in the trials.

Where it stands

Retatrutide has reached phase 3: large randomized trials. The first phase 3 results, from TRANSCEND-T2D-1 in type 2 diabetes, were published in 2026 4. Reaching phase 3 is not a license. A regulator has to review the whole program first, and none has recorded an authorization in the sources on its page.

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3: Retatrutide

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies

    First studies in people: safety, and how the body handles it.

  5. Cells and animals

    Laboratory and animal work. An animal result is not a result in people.

219
papers on PubMed
133
of them in people
11
randomized trials
136
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

From first trial to today

Retatrutide: year by year. Scroll sideways for the whole ribbon.

  1. 2019

    The phase 1b trial in type 2 diabetes begins enrolling in December, at four centers in the USA 5.

  2. 2021

    The phase 2 obesity trial is registered and randomizes its first participants; the phase 2 diabetes trial begins 210.

  3. 2022

    The discovery paper and the phase 1b results are published under the code LY3437943 56.

  4. 2023

    The phase 2 results in obesity and in type 2 diabetes are published 12.

  5. 2024

    The MASLD substudy is published; TRANSCEND-T2D-1 begins randomizing; a head-to-head trial against tirzepatide is registered 3412.

  6. 2025

    A systematic review and meta-analysis pools four placebo-controlled trials 7.

  7. 2026

    The TRANSCEND-T2D-1 results and the TRANSCEND-CKD design paper are published 49.

Sources

The numbers are those of the Retatrutide page, where every source is listed.

  1. 1Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England Journal of Medicine, 2023
  2. 4Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet, 2026
  3. 5Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet, 2022
  4. 6Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 2022
  5. 8Folli F, Finzi G, Manfrini R, et al. Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets. American Journal of Physiology. Endocrinology and Metabolism, 2023
The full Retatrutide page

Read next